Canntab Therapeutics (CSE:PILL-OTCQB:CTABF) CFO Richard Goldstein joined Steve Darling from Proactive Investors Vancouver on Skype to discuss their partner receiving their sale for medical purposes” license by Health Canada.
That designation means Canntab is very close to being in a position to sell its products and generate revenue. The license allows Canntab to produce samples of capsules containing CBD and/or THC, which, once approved by Health Canada, will enable the company to launch production and sales.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE